Who are Bifidobacterium infantis 35624's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Akkermansia muciniphila + Infliximab, Probiotic Vivomixx, Mesalazine plus Lactobacillus casei, Lactobacillus Fermentum, Synbiotic 2000, "AS-Probionorm".

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bifidobacterium-infantis-35624.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bifidobacterium infantis 35624 — Competitive Intelligence Brief

Bifidobacterium infantis 35624 (Bifidobacterium infantis 35624) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Gastroenterology.

phase 3 Probiotic Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Bifidobacterium infantis 35624 (Bifidobacterium infantis 35624) — Procter and Gamble. Bifidobacterium infantis 35624 is a live probiotic bacterium that modulates the gut microbiota and intestinal immune function to reduce gastrointestinal symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bifidobacterium infantis 35624 TARGET	Bifidobacterium infantis 35624	Procter and Gamble	phase 3	Probiotic
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
Probiotic Vivomixx	Probiotic Vivomixx	University of Milan	marketed	Probiotic
Mesalazine plus Lactobacillus casei	Mesalazine plus Lactobacillus casei	Hospital Cristo Re	marketed	Anti-inflammatory agent plus probiotic combination
Lactobacillus Fermentum	Lactobacillus Fermentum	HEM Pharma Inc.	marketed	Live biotherapeutic / Probiotic
Synbiotic 2000	Synbiotic 2000	Beth Israel Medical Center	marketed	Synbiotic (prebiotic + probiotic combination)
"AS-Probionorm"	"AS-Probionorm"	Industrial Microbiology LLP	marketed	Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bifidobacterium infantis 35624 — Competitive Intelligence Brief. https://druglandscape.com/ci/bifidobacterium-infantis-35624. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab